Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 8Tumor-Agnostic 3Lymphoid 3Genitourinary 3Dermatologic 3Thoracic 2Gynecologic 2Sarcoma 1Other solid neoplasm 1Head & Neck 1Breast 1

Conditions

Carcinoma, Renal Cell 13Carcinoma, Non-Small-Cell Lung 7Triple Negative Breast Neoplasms 5Melanoma 5Kidney Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasm Metastasis 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Mesothelioma 2Endometrial Neoplasms 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Adenocarcinoma Of Esophagus 2von Hippel-Lindau Disease 1Uveal Melanoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Spinocerebellar Degenerations 1Sarcoma 1Pheochromocytoma 1Paraganglioma 1Neoplasms, Unknown Primary 1Lung Neoplasms 1Liver Neoplasms 1

Interventions

Docetaxel 35pembrolizumab 32Nivolumab 27enzalutamide 20Prednisone 20Sunitinib 16Cyclophosphamide 16aldesleukin 14Zoledronic Acid 13Interleukin-2 13Gemcitabine 13Bevacizumab 13Specimen Handling 12Ipilimumab 12Radiosurgery 11Everolimus 11Androgen Antagonists 11Abiraterone Acetate 11fludarabine 10Sorafenib 10Radiotherapy 10Paclitaxel 10Magnetic Resonance Spectroscopy 10pazopanib 9abiraterone 9Doxorubicin 8Carboplatin 8Biopsy 8avelumab 7temsirolimus 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasm Metastasis × spartalizumab × Genitourinary × Clear all
NCT02964078 2026-04-02

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
27 enrolled 10 charts
Genitourinary

Kidney Diseases, Kidney Neoplasms, Neoplasm Metastasis

NCT03991130 2025-02-06

High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

University of California, San Diego

Phase 2 Terminated
6 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis

NCT04385654 2020-05-13

Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma

West China Hospital

Phase 2 Unknown
40 enrolled
Genitourinary

Kidney Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡